Attached files
| file | filename |
|---|---|
| EX-32.1 - CERTIFICATION - Panbela Therapeutics, Inc. | cimarron_ex321.htm |
| EX-31.2 - CERTIFICATION - Panbela Therapeutics, Inc. | cimarron_ex312.htm |
| EX-31.1 - CERTIFICATION - Panbela Therapeutics, Inc. | cimarron_ex311.htm |
| 10-Q - FORM 10-Q - Panbela Therapeutics, Inc. | cimarron_10q.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cimarron Medical, Inc. (the “Company”), on Form 10-Q for the period ended June 30, 2015, as filed with the Securities and Exchange Commission (the “Report”), I, David Fuhrman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Date: August 13, 2015 | By: | /s/ David Fuhrman |
|
|
|
| David Fuhrman |
|
|
|
| Chief Financial Officer |
|